Barrett’s Esophagus

Cellvizio facilitates the surveillance and treatment of Barrett’s Esophagus

Cellvizio may aid in detecting more dysplastic lesions 1 2  in Barrett’s Esophagus with fewer biopsies , and orient immediate endoscopic therapy.

See how Dr Joseph Burnette, a general surgeon with special interest in reflux uses Cellvizio on all his chronic reflux patients. By bringing the microscope to the patient, Dr Burnette is able to see more of the lining of the esophagus, the tissue that could be potential Barrett's esophagus or potential pre-malignant tissue.

Simple image recognition allows to differentiate between benign mucosa from pre-malignant changes and cancer.

Cellvizio Optical Biopsy is a through-the-scope procedure that fits any standard practice and equipment. Cellvizio has a rapid learning curve thanks to a comprehensive onboarding program.

  •  
  •  
 

Clinical studies have shown that Cellvizio may help in the detection of dysplastic lesions 1 2

The use of this technology may make surveillance endoscopy in BE more efficient and may lead to better informed patient management in real time for immediate endoscopic treatment

 

Prateek Sharma, MD

University of Kansas Medical Center, Kansas City, MO, USA 1


References:

  1. Sharma P. et al. Real-time Increased Detection of Neoplastic Tissue in Barrett’s Esophagus with probe- based Confocal Laser Endomicroscopy: Final Results of a Multi-center Prospective International Randomized Controlled Trial. Gastrointestinal Endoscopy, 2011.
  2. Bertani H. et al. Improved. Detection of Incident Dysplasia by Probe-Based Confocal Laser Endomicroscopy in a Barrett’s Esophagus Surveillance Program.
    Digestive Diseases and Sciences, 2013.
  3. Konda V.J. et al. Confocal laser endomicroscopy: potential in the management of Barrett’s esophagus. Diseases of the Esophagus, 2010.
  4. Johnson E.A. et al. Probe-Based Confocal Laser Endomicroscopy to Guide Real-Time Endoscopic Therapy in Barrett’s Esophagus with Dysplasia. Case Reports in Gastroenterology, 2012.
  5. The DONT BIOPCE clinical trial, GE, 2011